Inside IPEC: Regulation for Excipients is Brewing Across the Atlantic - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Inside IPEC: Regulation for Excipients is Brewing Across the Atlantic
Without any GMP guidelines for excipients in Europe, change can't come soon enough for some industry groups.

Pharmaceutical Technology
Volume 33, Issue 2, pp. 86-87

Interim standards

In the absence of any regulatory framework for GMPs, IPEC–Europe and EFCG are developing a third-party certification system. The project "could go a long way toward improving quality and, by extension, patient safety," says Iain Moore, chair of IPEC–Europe's GMP committee. IPEC–Europe and EFCG plan to consult the GMP auditing arm of IPEC–Americas known as IPEA (International Pharmaceutical Excipients Auditing).

Such an approach would allow third-parties such as BSI British Standards or SGS, which provide International Organization for Standardization (ISO 9001) certificates, to certify that excipient suppliers are operating according to GMP and GDP (good distribution practice) principles. The appropriate regulatory authority would provide accreditation to the auditing bodies, explained Tim Boelke, head of EFCG's excipient task force.

With thousands of excipients and suppliers serving the pharmaceutical industry, auditing every potential supplier is a daunting if not impossible task. Much like the situation in the US, Boelke believes the EU regulatory bodies lack the resources to carry out so many audits on their own. The authorities, however, can play an important role in auditing by providing independent oversight and monitoring the process, he says.

Third-party audits are included in the EC's pharmaceutical package but for APIs rather than excipients. In the package proposal, the regulatory authority's role would be to certify third-party auditing bodies who would then assess the GMP-compliance of API suppliers.

IPEC–Europe and EFCG, along with the United Kingdom's Pharmaceutical Quality Group, are developing a framework for certification of potential third-party auditors, including an excipient classification scheme and criteria for auditor qualification, training, and competency. The classification scheme, which may define a GMP level associated with the level of risk to patients, for example, is a top priority for the councils.

"We need to deliver a draft scheme quickly, as our aim is to present this and a detailed project plan to an invited group of stakeholders early in 2009 for their comment and feedback," says Moore.

At press time, IPEC–Europe's annual general meeting was taking place in France. Many of the issues addressed here were discussed and will be reported on at http://www.ipec–

Phil Taylor is a consultant and writer for the International Pharmaceutical Excipients Council of Europe (IPEC–Europe),
. IPEC is made up of four independent associations: the Americas, China, Japan, and Europe (


1. Europe Economics, Excipients: Impact Assessment Report (London), Dec. 19, 2007, available at, accessed Jan. 13, 2009.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here